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PDL1 blockade produces remarkable clinical re-
sponses, thought to occur by T cell reactivation
through prevention of PDL1-PD1 T cell inhibitory in-
teractions. Here, we find that PDL1 cell-intrinsic
signaling protects cancer cells from interferon (IFN)
cytotoxicity and accelerates tumor progression.
PDL1 inhibited IFN signal transduction through a
conserved class of sequence motifs that mediate
crosstalk with IFN signaling. Abrogation of PDL1
expression or antibody-mediated PDL1 blockade
strongly sensitized cancer cells to IFN cytotoxicity
through a STAT3/caspase-7-dependent pathway.
Moreover, somatic mutations found in human carci-
nomas within these PDL1 sequence motifs disrupted
motif regulation, resulting in PDL1 molecules with
enhanced protective activities from type I and type
II IFN cytotoxicity. Overall, our results reveal a
mode of action of PDL1 in cancer cells as a first line
of defense against IFN cytotoxicity.INTRODUCTION
Programmed death 1 ligand 1 (PDL1) is a member of the B7 fam-
ily of co-stimulatory/co-inhibitory molecules expressed by a
wide variety of cell types, including tumors (Sharpe et al.,
2007). PDL1 is a transmembrane protein consisting of an immu-
noglobulin-like extracellular part, followed by a transmembrane
domain and a short intracytoplasmic domain. Programmed
death 1 (PD1) is its prototypical receptor, which is expressed
mainly by effector immune cells such as B and T cells (Freeman
et al., 2000; Zak et al., 2015). However, PDL1 can also bind CD80
(Butte et al., 2007). The physiological role of PDL1 is to maintain
peripheral tolerance and contribute to antigen presentation to
T cells by dendritic cells (Karwacz et al., 2011; Sharpe et al.,1818 Cell Reports 20, 1818–1829, August 22, 2017 ª 2017 The Autho
This is an open access article under the CC BY-NC-ND license (http://2007). In neoplastic conditions, PDL1 tumor expression strongly
correlates with increased progression and poor prognosis, being
an indicator of resistance to conventional treatments such as
chemotherapy and radiotherapy.
It is widely accepted that PDL1 protects cancer cells by
engaging with PD1 expressed on the surface of activated cyto-
toxic T cells (Fife et al., 2009). This engagement is strongly inhib-
itory to T cells and leads to decreased effector activities. As a
consequence, PDL1-engaged PD1 in T cells interferes with the
T cell receptor (TCR) signalosome stopping T cell cytotoxic ac-
tivities and production of cytokines such as interferons (IFNs)
(Fife et al., 2009; Karwacz et al., 2011). Recent evidence sug-
gests that PDL1 can activate intrinsic signals in the absence of
PD1 that enhance cell proliferation and survival through the inhi-
bition of autophagy and mTOR activation (Clark et al., 2016;
Chang et al., 2015). However, in contrast to PD1, there is still
very little evidence for specific signal transduction events
induced by PDL1. No obvious sequence motifs in the intracyto-
plasmic domain with signal transduction capacities have been
either predicted or identified so far (Azuma et al., 2008).
PDL1/PD1 blockade therapy has achieved unprecedented
therapeutic clinical success for a variety of cancers, including
melanoma. PDL1/PD1-blocking antibodies cause the recovery
of T cell anti-tumor cytotoxicity and production of IFNs that
inhibit tumor cell growth and survival. Therefore, a significant
number of treated patients experience long-lasting anti-tumor
responses (Hodi et al., 2016). However, a large number of pa-
tients are still intrinsically resistant to anti-PDL1/PD1 therapy or
exhibit tumor progression after a period of therapeutic re-
sponses. Recently, it has been shown that inactivatingmutations
in JAK1, JAK2, and b2-microglobulin genes in cancer cells are
responsible for primary and acquired resistance to anti-PD1
therapy in a cohort of cancer patients (Shin et al., 2017; Zaretsky
et al., 2016). As IFN signals are potent transcriptional transacti-
vators of PDL1, these mutations inhibited PDL1 upregulation in
cancer cells. The authors proposed that the loss of PDL1 upre-
gulation abrogated the antitumor efficacy of PDL1/PD1 blockade
in these patients (Sharma et al., 2017).rs.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. PDL1 Protects Melanoma Cells from IFNb Toxicity
(A) Lentivector expression vectors used in the studies. LTR, long terminal repeats; SFFV, spleen focus-forming virus promoter; mPDL1, microRNA targeting
murine PDL1; UBIp, ubiquitin promoter; PuroR, gene conferring puromycin resistance.
(B) Expression of surface PDL1 in B16 cells treated with recombinant IFNb or transduced with the IFNb-expressing lentivector. Data are shown as flow cytometry
histogram plots. Numbers and percentages indicate mean fluorescent intensities and percentage of positive cells compared to the unstained (US) control.
(C) Left: flow cytometry histograms for PDL1 or IFNAR1 surface expression (as indicated) in the B16 cell lines as shown on the right of the histograms. Numbers
and percentages indicate mean fluorescent intensities and percentage of positive cells. Right: bar graphs representing the mean relative number of cells with
(legend continued on next page)
Cell Reports 20, 1818–1829, August 22, 2017 1819
Here, we demonstrate that PDL1 expression represents a
direct line of defense for cancer cells by transducing signals
that counteract IFN signal transduction within cancer cells.
Moreover, we demonstrate that the PDL1 intracytoplasmic
domain is essential for its protective functions through the activ-
ity of regulatory non-classical signal transduction motifs.
RESULTS
IFNb Expression Coupled to PDL1 Silencing Is Lethal to
Melanoma Cells
To engineer an immunogenic cell-based cancer vaccine, we
attempted to generate a B16F10 melanoma cell line with
silenced PDL1 that would secrete IFNb. To achieve this, we
cloned the IFNb gene into a lentivector expressing a PDL1-tar-
geted microRNA (mPDL1) and a puromycin selection gene pre-
viously described (Karwacz et al., 2011; Liechtenstein et al.,
2014a) (Figure 1A). Strikingly, although puromycin-resistant
cells could be obtained, these cells died within 1 or 2 weeks
of culture. To identify the component conferring lethality, the
IFNb gene was expressed with or without mPDL1 (Figure 1A).
Interestingly, it was possible to generate B16 cell lines express-
ing high levels of secreted IFNb (6 ng/mL) only in the absence of
mPDL1. As these cells had very high surface PDL1 protein
expression (Figure 1B), this indicated that PDL1 upregulation
could be an adaptation to survival from sustained IFNb
signaling. These results suggested that cancer cells may utilize
PDL1 expression to negatively regulate IFN signal transduction.
To confirm that the toxicity associated with PDL1 silencing was
mediated through enhanced IFNb signaling, B16 cells with a
silenced type I IFN receptor (B16-IFNAR1KD) were generated
using lentivector delivery of shRNA. Additionally, B16 cells
overexpressing a PDL1 mutant with reduced complementarity
to the mPDL1 (B16-PDL1) were also generated to strengthen
PDL1 signaling (Figure 1C). B16-IFNAR1KD cells proliferated
well regardless of whether they expressed IFNb or IFNb-mPDL1,
confirming that lethality was conferred by IFN signal transduc-
tion (Figure 1C). Importantly, PDL1 overexpression in B16
cells overcame the inhibitory effects of IFNb and the lethality
of the IFNb-mPDL1 combination (Figure 1C). Type I IFN receptor
is a homodimer of IFNAR1 and IFNAR2 molecules, of which
IFNAR1 is essential for signal transduction (Ragimbeau et al.,
2003). As B16-PDL1 cells showed levels of surface IFNAR1
and IFNAR2 expression comparable to unmodified B16 cells
(Figure 1C and not depicted), we concluded that PDL1 inter-
fered with IFNb signal transduction but did not cause IFNAR
downmodulation.error bars (SEM) after 2 weeks of puromycin selection following transduction of the
IFNb-PuroR or IFNb-mPDL1-PuroR. Data were obtained from 10 independent ex
(D) Left: flow cytometry histograms for PD1 surface expression in the indicated B
fluorescent intensities and percentage of positive cells. PD1DC indicates a PD1
resenting the mean relative number of cells with error bars (SEM) after 2 weeks
(bottom of the graphs) with lentivectors co-expressing IFNb-PuroR or IFNb-mPD
(E) Flow cytometry histograms for surface expression of PDL1 (left) or IFNAR1 (righ
indicate mean fluorescent intensities and percentage of positive cells. PDL1DC,
(F) Bar graphs representing the mean relative number of cells with error bars (SEM
B16 cell lines (bottom of the graphs) with lentivectors co-expressing IFNb-mPDL1
three independent experiments. Asterisks indicate very significant (**p < 0.01) an
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To test whether the engagement of PDL1 with its receptor PD1
would deliver a protective signal against IFNb cytotoxicity, we
generated B16 cell lines that constitutively expressed high levels
of PD1 or a mutant with a deletion of its intracytoplasmic domain
(PD1DC) incapable of signal transduction (Figure 1D). Both B16-
PD1 and B16-PD1DC cells significantly overcame the inhibitory
effects of IFNb expression, for which only the PD1 extracellular
part, but not its intracytoplasmic signaling domain, was required.
As expected, expression of IFNb, together with PDL1 silencing,
was still lethal to B16-PD1 and B16-PD1DC cells (Figure 1D).
These results demonstrated the requirement of PDL1 to transmit
a survival signal that is nevertheless potentiated by PD1
engagement.
To assess whether PDL1 possessed intrinsic signal transduc-
tion capacities that protected against IFNb toxicity, B16 cells
overexpressing a deletion mutant lacking the intracytoplasmic
domain (B16-PDL1DC) were generated. This PDL1 mutant did
not have the target sequence for mPDL1 and was efficiently ex-
pressed on the cell surface. Again, PDL1DC overexpression
did not alter the surface expression of IFNAR1 (Figure 1E and
not depicted). Unlike the wild-type version, the overexpression
of PDL1DC did not overcome the lethality conferred by the co-
expression of IFNb with mPDL1 (Figure 1E). Considering these
data, we concluded that PDL1 counteracts IFNb cytotoxicity
by signal transduction through its intracytoplasmic domain.
ConservedMotifs within the Intracytoplasmic Domain of
PDL1 Regulate Protection from IFNb Cytotoxicity
We then thoroughly analyzed the PDL1 intracytoplasmic domain
using several bioinformatics tools. PDL1 presents a strongly
amphiphilic intracytoplasmic domain without any obvious
signaling domains (Figure S1). After extensive searches using
different databases and algorithms, only MotifFinder produced
a positive hit with a domain present in a bacterial and eukaryotic
DNA-dependent RNA polymerase b subunit (Figure S1). No se-
quences related to signal transduction were found, suggesting
that PDL1 is using non-conventional signaling motifs.
Therefore, to identify PDL1 signal transduction functional
domains, we reasoned that these would be phylogenetically
conserved. The intracytoplasmic regions of 10 mammalian
PDL1 molecules were aligned, including the corresponding
sequence from salmon as a divergent control (Figure 2A). Three
conserved sequences were identified that we termed
‘‘RMLDVEKC,’’ ‘‘DTSSK,’’ and ‘‘QFEET’’motifs. PDL1undergoes
ubiquitination, which leads to its destabilization (Lim et al., 2016),
and we found that lysines 271 and 280 within RMLDVEKC andindicated B16 cell lines (bottom of the graphs) with lentivectors co-expressing
periments.
16 cell lines on the right of the plots. Numbers and percentages indicate mean
protein lacking the intracytoplasmic signaling domain. Right: bar graphs rep-
of puromycin selection following transduction of the indicated B16 cell lines
L1-PuroR. Data were obtained from 4 independent experiments.
t) on the indicated cell lines on the right of the plots. Numbers and percentages
PDL1 protein without the intracytoplasmic region.
) after 2 weeks of puromycin selection following transduction of the indicated
-PuroR. Relevant statistical comparisons are indicated within the graphs from
d highly significant (***p < 0.001) differences.
Figure 2. PDL1 Protection from IFNb Cytotoxicity Is Regulated by Conserved Sequence Motifs
(A) Alignment of the intracytoplasmic domain from PDL1 molecules of the indicated species. In red and blue are highly conserved residues. The consensus
sequence is shown on the bottom, with the three conservedmotifs within open boxes. Lysines predicted to be capable of undergoing ubiquitination are indicated
with arrows. Below the alignment are schemes indicating deletions or arginine substitutions.
(B) Left: real-time monitoring cell growth graphs from B16-PDL1KO cells reconstituted with the deletion mutants shown in (A), as indicated. Data are shown as
means from two independent cultures. Right: bar graphs plotting the cell index during the last 20 hr for eachmutant as indicated, using means from duplicates as
data for the analyses.
(C) As in (B) but using B16 cells expressing a PDL1mutant with DSK residuesmutated to alanines. Relevant statistical comparisons are indicatedwithin the graph.
***p < 0.001, highly significant difference.DTSSK motifs were putative targets for this post-translational
modification according to the application of a random forest algo-
rithm (Radivojac et al., 2010) (Figure 2A). To test the functionality
of these domains, B16 cells lacking PDL1 (B16-PDL1KO) were
generated using CRISPR/Cas9 (Figure S2). Then, a PDL1 gene
was constructed to prevent its cleavage by Cas9 through muta-
tion of the CRISPR/Cas9 target site while conserving the wild-
type amino acid sequence (PDL1wt). PDL1wt and mutants with
deletions of eachmotif were expressed in B16-PDL1KO cells (Fig-
ures 2A and S2). Two additional PDL1mutants with conservative
lysine-to-arginine substitutions were generated to eliminate the
possibility of PDL1 undergoing ubiquitinationwithin the intracyto-
plasmic domain (Figure 2A). All PDL1 mutants were efficiently
transported and expressed on the cell surface, as assessed by
flow cytometry following surface staining with PDL1-specific an-
tibodies (Figure S2). Then, the inhibitory activities of recombinantIFNb over these B16 modified cell lines were tested by real-time
monitoring of cell growth/viability (RTCA). An IFNb concentration
of 10 ng/mLwas chosen, as it caused at least 50%growth inhibi-
tion of B16-PDL1wt cells as assessed by RTCA. CRISPR/Cas9
abrogation of PDL1 (B16-PDL1KO) strongly sensitized B16 cells
to recombinant IFNb, even causing cell death (Figures 2B and
2C), in agreement with our initial observations based on IFNb
expression with a lentivector and also discarding potential off-
target effects of mPDL1 (Figure 1). PDL1 with a deleted QFEET
motif retained its protective capacities. In contrast, removal of
the RMLDVEKC motif completely abrogated anti-IFNb activity
(Figure 2B). Interestingly, deletion of the DTSSK motif as well as
lysine-to-arginine mutations within the RMLDVEKC or DTSSK
motifs significantly enhanced resistance to IFNb (Figure 2B).
These results strongly suggested that DTSSK was a regulatory
motif that modulates anti-IFN activity. To confirm this, theCell Reports 20, 1818–1829, August 22, 2017 1821
conservedD, S, andK residues in theDTSSKmotif weremutated
to alanines, and the resulting PDL1molecule was well expressed
on the surface of B16-PDL1KO cells (B16-DA cells). The alanine
replacement of these residues showed an enhancement of the
protective functions of PDL1 against IFNb, strongly reinforcing
the evidence that DTSSK is an inhibitory motif of PDL1’s protec-
tive functions (Figure 2C).
Overall, we concluded that the RMLDVEKC motif is essential
for PDL1’s protection against IFNb, while the DTSSK motif and
the lysines 271 and 280 act as negative regulators.
STAT3-Caspase-7 Is the Main Effector Pathway
Conferring IFNb Lethality to PDL1 Silencing
Type I IFNs exert their activities by engaging with its receptor,
IFNAR1/IFNAR2, on the cell surface. The main signal cascade
depends on the recruitment of janus kinase 1 (JAK1) and
TYK2, which phosphorylates signal transducer and activator of
transcription (STAT)1, STAT2, and STAT3, which associate into
STAT1/STAT2 heterodimers or STAT1/STAT1 and STAT3/
STAT3 homodimers. In addition, type I IFNs cause caspase-
dependent apoptosis, although the exact mechanisms are yet
unclear. To identify the downstream effectors leading to exacer-
bated toxicity by lack of PDL1, B16 cell lines were generatedwith
a selection of key components of the IFN signal transduction
pathway silenced (Figure 3A).
These cell lines were tested in the IFNb survival assay as
described above (Figure 1). As expected, IFNAR1 and JAK1
silencing abrogated IFNb toxicity. Interestingly, silencing of
STAT3 and caspase-7 (CASP7) also reduced IFNb inhibitory ef-
fects (Figure 3B). Moreover, lethality of the IFNb-mPDL1 combi-
nation was only averted by silencing IFNAR1, JAK1, STAT3,
and CASP7 (Figure 3C). To find out whether the absence of
PDL1 signals enhanced IFNb signal transduction, the expression
of STATs was assessed in B16 and CRISPR/Cas9 PDL1
knockout B16 cells after IFNb treatment for 24 hr (Figure 3D).
STAT1 and STAT2 were upregulated to the same extent in B16
and PDL1KO cells. In contrast, STAT3 levels increased only in
PDL1KO cells in response to IFNb. Then, we performed a time-
course assay of STAT3 phosphorylation after IFNb stimulation.
Interestingly, STAT3 Y705 phosphorylation was stronger and
occurred faster in PDL1KO cells, while STAT3 S727 phosphoryla-
tion remained unchanged in B16 and in B16-PDL1KO cells
(Figure 3E). These results indicated that PDL1 signals were inhib-
iting STAT3 Y705 phosphorylation and prevented STAT3
upregulation.
Survival assays with CASP-silenced B16 cell lines suggested
that interference with PDL1 expression was causing cell death
in response to IFNb through CASP7. Our results also indicated
that cell death was largely caused by apoptosis rather than
CASP-independent necroptosis, although the participation of
this last mechanism cannot be completely ruled out. To confirm
these results, RTCA was performed with CASP-silenced B16
cells or CASP-silenced B16-PDL1KO cell lines in response to
recombinant IFNb (Figure 3F). While CASP3 silencing did not
abrogate toxicity to recombinant IFNb, CASP7 silencing in-
hibited IFNb inhibitory actions. The same results were also
observed in B16-PDL1KO cells, although in this assay, CASP9
silencing counteracted toxicity as well. Then, the expression1822 Cell Reports 20, 1818–1829, August 22, 2017and processing of effector CASPs in B16 cells after treatment
with recombinant IFNb was compared to B16-PDL1KO cells.
Overall, basal expression of CASP3, 7, and 9 were increased in
B16-PDL1KO cells, especially after IFNb treatment (Figure 3G).
In agreement with the small hairpin RNA (shRNA) data, the pro-
cessing of CASP7 was strongly enhanced in B16-PDL1KO
following IFNb treatment (Figure 3F). Overall, these data sug-
gested that the effector pathway for IFNb cytotoxicity caused
by PDL1 silencing was mainly mediated by a reinforced
STAT3-CASP-7 pathway.
Antibody-Mediated PDL1 Blockade Abrogates the
Protective Functions of PDL1 in Murine and Human
Cancer Cell Lines
To test whether direct blockade of PDL1 could sensitize B16 and
other murine and human cancer cells to IFNb, the growth and
viability of murine B16, CT26 colorectal, and 4T1 breast cancer
cells weremonitored by RTCA in the presence of increasing con-
centrations of a PDL1-blocking antibody or an isotype control
(Figures 4A–4C). PDL1 antibody blockade sensitized all three
murine cancer cell types to recombinant IFNb. The same results
were obtained with human B-RAF mutated melanoma HTB72
cells. Taken together, these results confirmed that the anti-
IFNb mechanism regulated by PDL1 is conserved in murine
and human cancer cells.
Somatic Mutations in Human Cancers Targeting the
DTSSK Domain Strongly Potentiate Global Anti-IFN
Activities of PDL1
Our data strongly suggested that cancer cells rely on PDL1
signal transduction to counteract IFN toxicity. As this could be
relevant for human immunotherapy, we studied the somatic mu-
tations within the intracytoplasmic domain of PDL1 in human
neoplastic malignancies. The catalogue of somatic mutations
in cancer (COSMIC), ICGC, Intogen, and TCGA catalogs of
somatic mutations in cancer were consulted, and several
mutations leading to amino acid changes were identified in car-
cinomas, including skin and lung cancers. Interestingly, the
majority of these (5 out of 7) directly affected the human homolog
of the DTSSK motif (Figure 5A). To test the effects of these mu-
tations over PDL1’s protective functions, the twomost disruptive
mutations (D276H and K280N) were introduced into the equiva-
lent murine PDL1 gene, and B16-PDL1KO cells were transduced
to express each mutant.
Then, RTCA was used to monitor the growth and survival of
the B16 cell lines in the presence of recombinant IFNb (Fig-
ure 5B), IFNa (Figure 5C), and IFNg (Figure 5D). Consistent
with our previous results, these mutations within the DTSSK
motif strongly enhanced resistance to cytotoxicity mediated
by type I and type II IFNs, while B16-PDL1KO cells were highly
sensitive to IFNa, IFNb, and IFNg. These results confirmed
the regulatory role of the DTSSK motif by selection of variants
in human carcinomas that disrupt its inhibitory activity leading
to hyperactive PDL1 proteins. Moreover, these mutations
extended wide protection from IFNa and IFNg. Finally, the inhib-
itory activity of DTSSK was not exclusively dependent on lysine
280, as the D276H mutation also enhanced protective activity
of PDL1.
Figure 3. IFNb-Enhanced Cytotoxicity by PDL1 Silencing Depends on a STAT3-CASP7 Pathway
(A) Western blots of the specific signal transduction molecules as shown on the left in B16 cell lines constitutively expressing the shRNAs indicated on top.
(B) Bar graphs representing the mean relative number of cells with error bars (SEM) after 2 weeks of puromycin selection following transduction of the indicated
B16 cell lines (with the indicated silenced genes as shown) with lentivectors co-expressing IFNb-PuroR.
(C) Same as in (B), but transductions were performed with lentivectors co-expressing IFNb-mPDL1-PuroR.
(D) Detection by western blotting of the indicated STAT molecules in B16 or B16-PDL1KO cells untreated or treated with IFNb as shown on top.
(E) Western blot of STAT3 Y705 phosphorylation (top) at the indicated time points in B16 and B16-PDL1KO cells after IFNb stimulation, as indicated. Western blot
(bottom) of STAT3 S727 phosphorylation in B16 or B16-PDL1KO cells after IFNb stimulation, as indicated.
(F) Bar graphs representing RTCA cell index of the indicated B16 cell lines with silenced CASPs either in an unmodified or PDL1KO background as shown in the
graphs in the presence of 10 ng/mL recombinant IFNb.
(G) As in (D) but with detection of the indicated CASPs.
(H) Western blot of processed CASP7 on a time course of B16 or B16-PDL1KO cells treated with 10 ng/mL recombinant IFNb as shown on top. Relevant statistical
comparisons are indicated within the graphs. Asterisks indicate significant (*p < 0.05), very significant (**p < 0.01), and highly significant differences (***p < 0.001).PDL1 Signal Transduction in Cancer Cells Is Required
for In Vivo Protection against IFNb
Our data collectively suggested that PDL1 intrinsic signaling
within cancer cells would confer resistance to IFNs in vivo inde-
pendently of its inhibitory role over T cells. To prove this, we stud-
ied in vivo tumor growth fromB16 cells in which PDL1 expression
or signaling were altered, followed by intra-tumor administrationof IFNb expressed by a lentivector or a GFP-expressing control.
First, groups of mice were subcutaneously inoculated with B16,
B16-PDL1, and B16 cells harboring a published PDL1-targeted
shRNA, which reduced the basal expression of PDL1 (Broos
et al., 2017) (Figure 6A). Then, lentivectors expressing either
GFP (control) or IFNb-GFP were injected into tumors 7 and
14 days later. Intra-tumor expression of IFNb-GFP delayedCell Reports 20, 1818–1829, August 22, 2017 1823
Figure 4. PDL1 Blockade Sensitizes Murine and Human Cancer Cells to IFNb
(A) Left: RTCA graph of murine B16 melanoma cells in the presence of recombinant IFNb and the indicated concentrations of anti-PDL1 antibody. Right: same
data as a bar graph but with means and SD with error bars (n = 4).
(B) Same as (A) but with murine CT26 colorectal cancer cells.
(C) Same as (A) but with murine 4T1 breast cancer cells.
(D) Same as (A) but with human HTB72 melanoma cells. Calculated IC50 values are shown within the graphs. ***p < 0.001, highly significant difference.B16 melanoma tumor growth (Figure 6A). PDL1 overexpression
completely abrogated this sensitivity to IFNb-GFP. In contrast,
tumors arising from B16-shPDL1 were highly sensitive to LV-
IFNb-GFP, resulting in a significant delay in tumor growth and
increased survival (Figure 6A). We repeated the experiment
using B16-PDL1KOcells. As expected, tumors arising from
B16-PDL1KO cells were highly responsive to intra-tumor lenti-
vector delivery of IFNb-GFP, leading to a highly significant
increase in survival (Figure 6B). In fact, the lack of PDL1 was suf-
ficient to delay tumor progression even in the absence of intratu-
mor expression of IFNb (Figure 6B).
These results showed a higher sensitivity in these B16 tumors
to IFNbwhen PDL1 expression was interfered with. However, in-
hibition of PDL1 expression in cancer cells could still enhance
the cytotoxicity of T cells through reduced PDL1-PD1 engage-
ment. Therefore, we carried out the same experiments but
included a group in which B16-PDL1DC cells were inoculated.
PDL1 in these cells can still engage PD1 on the surface of
T cells but with impaired signal transduction within cancer cells
(Figure 1). Then, tumors from B16, B16-PDL1, and B16-PDL1DC
were inoculated with lentivectors expressing IFNb-GFP. As ex-
pected, PDL1 overexpression in B16 cells very significantly
counteracted the inhibitory effects of IFNb and accelerated tu-
mor progression (Figure 6C). In contrast, expression of PDL1DC
did not confer resistance to intra-tumor delivery of IFNb. As this
mutant can still engage PD1 on T cells, these results indicate that
PDL1 signal transduction contributes significantly to protection
of cancer cells from type I IFNs. Overall, these results showed1824 Cell Reports 20, 1818–1829, August 22, 2017that independently of its role in inhibiting cytotoxic T cells,
PDL1 provides a first protective barrier to cancer cells by inter-
fering with IFN signal transduction.
DISCUSSION
IFNs are known to exert anti-tumor effects, which include CASP-
dependent apoptosis (Apelbaum et al., 2013), cell growth arrest
(Vannucchi et al., 2000), and cell senescence (Katlinskaya et al.,
2016; Yu et al., 2015). IFNs play a critical role in anti-cancer im-
mune responses and contribute to the efficacy of conventional
treatments and immunotherapies. There is ample evidence on
the role that IFNs play in tumor repression, immune editing,
and progression (Zitvogel et al., 2015). Many treatments,
including chemotherapy and targeted therapies, need an intact
IFN signal transduction pathway in cancer cells to exert their
anti-tumor effects. However, type I IFNs in progressing tumors
also drive immune editing (Smyth, 2005). In fact, acquisition of in-
activating mutations affecting IFN signaling could be considered
a core mechanism for tumor escape and progression. Recently,
it has been shown that inactivating JAK1, JAK2, and b2-micro-
globulin mutations in cancer cells are responsible for primary
and acquired resistance to anti-PD1 treatment in a cohort of pa-
tients (Shin et al., 2017; Zaretsky et al., 2016). The authors of
these studies proposed that switching off IFN signal transduc-
tion prevented the adaptive PDL1 expression in cancer cells,
becoming functionally PDL1 negative and refractory to PDL1/
PD1 blockade. However, PDL1 itself can transmit signals without
Figure 5. Somatic Mutations in the Human
DTSSK Homolog Motif Lead to Hyperactive
PDL1 Molecules that Protect Cells from
Type I and Type II IFNs
(A) Schematics on the distribution of somatic mu-
tations foundwithin the intracytoplasmic domain of
human PDL1. Blue, green, and red are used to
show the homologous human RMLDVEKC,
DTSSK, and QFEET motifs. Mutations are shown
below, with conservative changes in green and
non-conservative changes in red. The specific
carcinomas for which mutations were described
are indicated within boxes. Numbers represent
amino acid positions in the murine and human
PDL1 molecule.
(B) The two most disruptive mutations were intro-
duced in the DTSSK murine motif and the resulting
PDL1 molecules expressed in B16-PDL1KO cells.
Left: RTCA plot of the indicated B16 cell lines
expressing the PDL1 mutants compared to
PDL1wt in the presence of 10 ng/mL recombinant
IFNb. Right: the same data as bar graphs repre-
senting the mean of the normalized cell index
from duplicate cultures, together with SDs as error
bars.
(C) As in (B) but with IFNa. PDL1KO indicates
B16 cells in which PDL1 was disrupted with
CRISPR/Cas9.
(D) As in (B) but with IFNg. Relevant statistical
comparisons are indicated within the graph.
***p < 0.001, highly significant difference.engaging PD1 or CD80 through mTOR (Clark et al., 2016; Chang
et al., 2015). Here, we demonstrate that PDL1 signal transduc-
tion in murine and human cancer cells does in fact represent a
barrier of protection against IFN cytotoxicity by inhibitory
crosstalk with the type I IFN signal transduction pathway. It is
important to emphasize that basal PDL1 expression reduces
IFN cytotoxicity but does not completely abrogate it. Therefore,
cancer cells respond to IFNs by upregulating the surface expres-Cell Repsion of PDL1, possibly as a negative
feedback mechanism to regulate IFN
signaling. It has to be taken into account
that IFNs are potent transcriptional acti-
vators of PDL1 (Zaretsky et al., 2016).
PDL1 possesses a short intracytoplas-
mic region without any obvious known
domains regulating signal transduction.
However, it has been shown by others
and us that there is PDL1 intrinsic
signaling regulating cell growth, survival,
and protection against apoptotic signals
(Azuma et al., 2008; Clark et al., 2016;
Chang et al., 2015; Liechtenstein et al.,
2014a). We have identified functional
regulatory sequence motifs within the
intracytoplasmic domain responsible for
PDL1 protection against IFN. The
conserved RMLDVEKC motif is required
to counteract IFNb toxicity, while theDTSSK motif and arginines 271 and 280 act as negative regula-
tors of PDL1 functions. These sequences constitute non-clas-
sical signal transduction motifs, as they do not resemble any
known signal transduction consensus. Only the sequence
EKCGVEDTSSKNR shows high similarity to a domain in DNA-
directed RNA polymerase subunit b, which interestingly includes
the DTSSK motif (Figure S1). However, the relevance of this
observation is unclear.orts 20, 1818–1829, August 22, 2017 1825
Figure 6. PDL1 Intrinsic Signaling in Cancer Cell Protects Tumors from IFNb In Vivo
(A) Left: tumor growth graphs from injected B16 cells followed by intratumor injection with the indicated lentivectors, represented as means of tumor surfaces
from groups of 6 mice with SDs as error bars. The middle and right graphs as in the left graph but using the indicated B16 cell lines overexpressing PDL1
(B16-PDL1) or B16 cell lines expressing a PDL1-targeted shRNA (B16-shPDL1).
(B) The growth graph as in (A) but using B16 wild-type or B16 PDL1 knockout cells. The graph on the right represents the time of death of each mouse from the
data shown on the left graph. The cell lines and the injected lentivectors are shown on the bottom of the graph.
(C) Same as in (B) but using B16 wild-type, B16-PDL1, or B16-PDL1DC cells, which express a PDL1 mutant lacking the intracytoplasmic domain. Asterisks
indicate very (**p < 0.05) and highly (***p < 0.001) significant differences.Our findings also show that PD1 expression protects cancer
cells from IFNb toxicity by engaging PDL1. Hence, both PDL1
and PD1 blockade would sensitize cancer cells to IFN-mediated1826 Cell Reports 20, 1818–1829, August 22, 2017cytotoxicity. Furthermore, we found that antibody-mediated
PDL1 blockade is sufficient to sensitize cancer cells to IFNs.
Therefore, any adaptation of cancer cells to either inhibit the
IFN signaling pathway (Shin et al., 2017; Zaretsky et al., 2016) or
potentiate PDL1 activities will favor their escape from the im-
mune attack. Accordingly, a variety of human carcinomas select
somatic mutations that affect residues within the inhibitory
DTSSK motif, thereby increasing the anti-IFN activity of PDL1.
These cancer cells with hyperactive PDL1mutants are very likely
selected in human malignancies as a result of immune editing.
Our data demonstrate that PDL1 signal transduction through
conserved signaling motifs represents a protective barrier of
cancer cells against IFN cytotoxicity, which would be reinforced
by its inhibitory properties to T cells when engaged with PD1.
A therapeutic approach such as PDL1/PD1 blockade would
cause rapid cancer cell death due to further sensitization to
IFN. This situation strongly favors the survival of variants resis-
tant to IFN signal transduction. Therefore, cancer cells with
mutated JAK1 or JAK2 kinases are intrinsically resistant to IFN
toxicity and do not show adaptive PDL1 upregulation (Shin
et al., 2017; Zaretsky et al., 2016).
EXPERIMENTAL PROCEDURES
Cells and Mice
HEK293T cells were purchased from the American Type Cell Culture Collec-
tion (ATCC). Murine melanoma B16F10 cells were grown as described previ-
ously (Liechtenstein et al., 2014a). Murine CT26 colorectal and 4T1 breast
cancer cells were grown in DMEM. Human HTB72 cells were grown in
RPMI. C57BL/6 female mice were purchased from The Jackson Laboratory.
Approval for animal studies was obtained from the Animal Ethics Committee
of the University of Navarra (Pamplona, Navarra, Spain) and from the Govern-
ment of Navarra. When indicated, recombinant IFNb was added to the cell
cultures at the appropriate concentrations. Cell growth and survival were
monitored in real time using the xCELLigence real-time cell analysis system
(RTCA, ACEA Biosciences) by seeding between 3,000 and 10,000 cells as
required, in the presence or absence of recombinant IFNb. Inhibitory concen-
tration 50 (IC50) was calculated by RTCA for B16 cell lines with increasing con-
centrations of recombinant IFNb. Experiments of antibody-mediated PDL1
blockade were carried out with anti-PD-L1 monoclonal antibody (clone
10B5) (Dong et al., 2002). For human PDL1 blockade, the in-house phage-
display engineered humanized immunoglobulin G1 (IgG1) recombinant anti-
body Plimilumab was used.
Plasmids
The FB2 fusokine transgene is described in (Van der Jeught et al., 2014) and
consists on a fusion gene between the murine IFNb and the ectodomain of
the TGFb receptor II. The FB2 transgene was cloned into the pDUAL-p1-PuroR
vector by standard cloning techniques. This vector contains a PDL1-targeted
microRNA and has been described previously (Liechtenstein et al., 2014a). The
IFNb coding sequence was amplified by PCR and cloned into pDUAL-mPDL1-
PuroR and pDUAL-GFP (Liechtenstein et al., 2014a). Likewise, the TGFbRII
was amplified by PCR, introducing the IFNb signal peptide for secretion at
the 50 end, and cloned into pDUAL-p1-PuroR. When required, the same trans-
genes were expressed without the PDL1-targeted microRNA. The pHIV-
SIREN lentivectors (Lanna et al., 2014; Liechtenstein et al., 2014b) were
used to express shRNAs targeting the indicated genes (Table S1) together
with blasticidin resistance. The PDL1 transgene was ordered from Geneart
and includes 7 silent mutations (ccaaagatctttatg, mutations underlined) and
6 silent mutations (agaaacgacacgcagttt) at the amino and C termini to prevent
its silencing by either mPDL1 or PDL1-targeted CRISP/CAS9. PDL1DC en-
codes a C-terminal deleted PDL1 gene and was generated by PCR using for-
ward (FW; ggatccgccaccatgaggatatttgctggc) and reverse (RS; cggccgcttattg
ttttctcaagaagaggaggaccg) oligos. PDL1-deletion and single-point substitution
mutants were generated by overlap-extension PCR as described (Escors
et al., 2001) using the PDL1 gene as a template and the indicated oligonucle-
otides (Table S2). The murine PD1 transgene was ordered from Geneart andcloned into pDUAL-BlastR, which expresses blasticidin resistance under the
control of the ubiquitin promoter. A C-terminal-deleted version was also gener-
ated by PCR using FW (ggggggatccgccaccatgtgggtccggcaggtacc) and RS
(gcggccgcttatgagcagaagacagctagggcccaggc) oligos, followed by cloning
into pDUAL-BlastR.
The mouse CD274 (PDL1) sgRNA CRISPR/Cas9 ‘‘All-in-One’’ lentiviral
transfer vector was used to knock out PDL1 as described previously (Broos
et al., 2017).
Lentivector Production, Cell Transduction, and Generation of B16
Knockdown Stable Cell Lines
Lentivector production and titration were carried out as described elsewhere
(Karwacz et al., 2011; Liechtenstein et al., 2014a; Selden et al., 2007). Trans-
duction of the indicated cell lines was carried out with a multiplicity of trans-
duction of 10, and transduced cells were selected with the appropriate
concentration of either puromycin (Gibco) or blasticidin (Gibco). Transduced
cells are then analyzed for the expression of the target of interest either by
flow cytometry or western blot.
Western Blotting
Western blots were performed as described previously (Escors et al., 2008).
Polyclonal anti-CASP-3, 7, 9 and anti-processed CASP-3, 7, and 9 and anti-
phosphorylated STAT3 molecules were purchased from Cell Signaling Tech-
nology. Mouse anti-JAK1, STAT1, STAT2, and STAT3 antibodies were
purchased fromCell Signaling Technology and anti-GADPH fromCalbiochem.
Peroxidase-conjugated polyclonal anti-mouse and anti-rabbit antibodies were
purchased from DAKO and Cell Signaling Technology.
Cell Staining and Flow Cytometry
Surface and intracellular staining were performed as described previously
(Escors et al., 2008) using the indicated antibodies. Phycoerythrin (PE)-Cy7-
conjugated streptavidin, antigen presenting cell (APC)-conjugated streptavi-
din, PE-conjugated anti-IFNARI were purchased from BioLegend. PE-and
fluorescein isothiocyanate (FITC)-conjugated streptavidin from Invitrogen.
Biotin-conjugated anti-PDL1 was purchased from eBioscience. APC-conju-
gated anti-PD1 was purchased from Miltenyi Biotec.
B16-IFNb Cell Survival Assays
The goal of this assay is to quantify viable growing B16 cell lines that consti-
tutively express IFNb following lentivector transduction with IFNb-PuroR or
IFNb-mPDL1-PuroR followed by selection with puromycin. For this assay,
100,000 of the indicated transduced or non-transduced cells were plated
in 6-well culture plates in triplicate. Cells were then transduced at a
multiplicity of transduction of 10. One well was left as a non-transduced con-
trol. The next day, puromycin was added at 1 mg/mL, and surviving cells
were allowed to grow for 2 weeks. Surviving cells were quantified and repre-
sented as a percentage compared to the growth of non-transduced, non-
treated cells.
IFN Treatment of PDL1 Mutants and Real-Time Living Cell
Monitoring
The appropriate cell types were seeded at a density of 5,000 cells per well on
two L8 cell culture chambers for xCELLingence RTCA monitoring system
(ACEA Biosciences). Cells were grown in DMEM or RPMI medium with recom-
binant murine or human IFNb (10 ng/mL, eBioscience) as required. Murine
IFNa (400 U/mL) and IFNg (10 ng/mL) were purchased from (PeproTech).
Growth and survival of cell lines were monitored by RTCA for a minimum of
3 days.
Vaccination and Tumor Experiments
Experiments were usually performed with six C57BL/6 mice per group.
Mice were subcutaneously inoculated with 106 of the indicated B16 cell lines.
Tumor size was monitored every 2 days. When required, tumors were injected
with 106 lentivector transducing particles expressing IFNb-GFP or with GFP
only as a control. Mice were sacrificed when tumor surface was above
150 mm2.Cell Reports 20, 1818–1829, August 22, 2017 1827
In Silico Sequence Analyses
PDL1 protein sequences from mouse, human, pig, cow, buffalo, cat, dog, and
salmon were aligned using the multialign tool (http://multalin.toulouse.inra.fr/
multalin/) (Corpet, 1988). Prediction of ubiquitination sites was performed
with the UbPred tool (http://www.ubpred.org/) (Radivojac et al., 2010). The
search for conserved protein domains was performed with MotifFinder
(http://www.genome.jp/tools-bin/search_motif_lib). The data on somatic mu-
tations in PDL1 from human cancers were obtained from the COSMIC
(http://cancer.sanger.ac.uk/cosmic) and TCGA (https://cancergenome.nih.
gov/) databases. The following mutations were found: R260C (colon and
cecum carcinoma; COSU3769), R262K (basal cell carcinoma; COSP39263),
I274I (lung, cecum carcinoma, and melanoma; COSP29675, COSU540, and
COSU17), I274V (colon carcinoma, COSU144), D276H (breast invasive carci-
noma; TCGA-AR-A0TX-01 and COSU414), D276Y (rectum carcinoma), T277K
(George et al., 2015) (small cell lung cancer; COSP40339), T277S (lung carci-
noma; COSP40399), K280N (cervical squamous cell carcinoma; TCGA-FU-
A3HZ-01 and COSU415), T290M (pancreas and stomach carcinomas;
TCGA-BR-4362-01 and COSU541), and T290T (breast cancer; COSU541).
Statistical Analyses
GraphPad Prism was used for plotting data and statistical analyses. No data
were considered outliers. Data from the B16-IFNb survival assay were
confirmed to be normally distributed and therefore analyzed by two-way
ANOVAs with a random criterion (inter-experiment variability). Two pair com-
parisons were carried out following the ANOVA analyses using either Bonfer-
roni or Tukey’s tests. Tumor growth and survival data were analyzed as
described before (Karwacz et al., 2011). ACEA RTCA cell index data were
analyzed for each sample in duplicate and plotted as means and SD. The
data were highly homogeneous and normally distributed. For statistical ana-
lyses, the cell index data were collected at 75, 80, 85, and 90 hr of cell growth.
The data were analyzed by two-way ANOVA with time as a random criterion
followed by Tukey’s pairwise comparisons.
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